Human C-type natriuretic peptide

effects on the haemodynamic and endocrine responses to angiotensin II

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    Objective: The aim was to study the effects of high dose systemic human C-type natriuretic peptide (CNP) infusion in man on systemic and pulmonary haemodynamics and the renin-angiotensin system before and after infusion of angiotensin II. Methods: Eight normal male volunteers were studied on two separate occasions when, after the subjects had been rested to reach a baseline haemodynamic state (T0), infusions of either human CNP (10 pmol·kg-1·min-1) or placebo (5% dextrose) were begun. After 30 min (T30) on each study day, a concomitant infusion of angiotensin II (6 ng·kg-1·min-1) was started, and both infusions ran together for a further 30 min (until T60). Measurements of systemic and pulmonary haemodynamic variables and the activity of the renin-angiotensin system were made at baseline (T0), after 30 min of CNP or placebo (T30), and after angiotensin II (T60). Results: Infusion of CNP had no significant effects on systemic or pulmonary haemodynamics or on baseline reninangiotensin system activity compared with placebo. Infusion of angiotensin II produced significant systemic and pulmonary pressor effects and also stimulated aldosterone secretion. There were, however, no significant differences between the changes induced by angiotensin II (expressed as the difference between T30 and T60) when CNP was infused compared with placebo: change in mean systemic arterial pressure with CNP 26.6(SEM 2.3) mm Hg v placebo 30.3(3.6) mm Hg; change in mean pulmonary artery pressure with CNP 11.7(2.5) mm Hg v placebo 10.9(1.0) mm Hg; change in aldosterone concentration with CNP 219(40) pmol·litre-1 v placebo 242(40) pmol·litre-1. Conclusions: At a dose of CNP which has previously been found to have marked haemodynamic effects in dogs, no effect on systemic or pulmonary haemodynamics was observed in man. Furthermore, CNP had no effect on the aldosterone or pressor responses to infused angiotensin II. The present study would suggest that CNP does not have a circulating endocrine role in cardiovascular homeostasis, although a paracrine role within vascular endothelium is perhaps more likely.

    Original languageEnglish
    Pages (from-to)108-111
    Number of pages4
    JournalCardiovascular Research
    Volume29
    Issue number1
    DOIs
    Publication statusPublished - 1995

    Fingerprint

    C-Type Natriuretic Peptide
    Natriuretic Agents
    Angiotensin II
    Hemodynamics
    Placebos
    Lung
    Aldosterone
    Renin-Angiotensin System
    Vascular Endothelium
    Pulmonary Artery
    Healthy Volunteers
    Arterial Pressure
    Homeostasis

    Cite this

    @article{6caf8607ec574ed39087540674a6025a,
    title = "Human C-type natriuretic peptide: effects on the haemodynamic and endocrine responses to angiotensin II",
    abstract = "Objective: The aim was to study the effects of high dose systemic human C-type natriuretic peptide (CNP) infusion in man on systemic and pulmonary haemodynamics and the renin-angiotensin system before and after infusion of angiotensin II. Methods: Eight normal male volunteers were studied on two separate occasions when, after the subjects had been rested to reach a baseline haemodynamic state (T0), infusions of either human CNP (10 pmol·kg-1·min-1) or placebo (5{\%} dextrose) were begun. After 30 min (T30) on each study day, a concomitant infusion of angiotensin II (6 ng·kg-1·min-1) was started, and both infusions ran together for a further 30 min (until T60). Measurements of systemic and pulmonary haemodynamic variables and the activity of the renin-angiotensin system were made at baseline (T0), after 30 min of CNP or placebo (T30), and after angiotensin II (T60). Results: Infusion of CNP had no significant effects on systemic or pulmonary haemodynamics or on baseline reninangiotensin system activity compared with placebo. Infusion of angiotensin II produced significant systemic and pulmonary pressor effects and also stimulated aldosterone secretion. There were, however, no significant differences between the changes induced by angiotensin II (expressed as the difference between T30 and T60) when CNP was infused compared with placebo: change in mean systemic arterial pressure with CNP 26.6(SEM 2.3) mm Hg v placebo 30.3(3.6) mm Hg; change in mean pulmonary artery pressure with CNP 11.7(2.5) mm Hg v placebo 10.9(1.0) mm Hg; change in aldosterone concentration with CNP 219(40) pmol·litre-1 v placebo 242(40) pmol·litre-1. Conclusions: At a dose of CNP which has previously been found to have marked haemodynamic effects in dogs, no effect on systemic or pulmonary haemodynamics was observed in man. Furthermore, CNP had no effect on the aldosterone or pressor responses to infused angiotensin II. The present study would suggest that CNP does not have a circulating endocrine role in cardiovascular homeostasis, although a paracrine role within vascular endothelium is perhaps more likely.",
    author = "Cargill, {Robert I.} and Struthers, {Allan D.} and Lipworth, {Brian J.}",
    year = "1995",
    doi = "10.1016/S0008-6363(96)88554-3",
    language = "English",
    volume = "29",
    pages = "108--111",
    journal = "Cardiovascular Research",
    issn = "0008-6363",
    publisher = "Oxford University Press",
    number = "1",

    }

    Human C-type natriuretic peptide : effects on the haemodynamic and endocrine responses to angiotensin II. / Cargill, Robert I.; Struthers, Allan D.; Lipworth, Brian J.

    In: Cardiovascular Research, Vol. 29, No. 1, 1995, p. 108-111.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Human C-type natriuretic peptide

    T2 - effects on the haemodynamic and endocrine responses to angiotensin II

    AU - Cargill, Robert I.

    AU - Struthers, Allan D.

    AU - Lipworth, Brian J.

    PY - 1995

    Y1 - 1995

    N2 - Objective: The aim was to study the effects of high dose systemic human C-type natriuretic peptide (CNP) infusion in man on systemic and pulmonary haemodynamics and the renin-angiotensin system before and after infusion of angiotensin II. Methods: Eight normal male volunteers were studied on two separate occasions when, after the subjects had been rested to reach a baseline haemodynamic state (T0), infusions of either human CNP (10 pmol·kg-1·min-1) or placebo (5% dextrose) were begun. After 30 min (T30) on each study day, a concomitant infusion of angiotensin II (6 ng·kg-1·min-1) was started, and both infusions ran together for a further 30 min (until T60). Measurements of systemic and pulmonary haemodynamic variables and the activity of the renin-angiotensin system were made at baseline (T0), after 30 min of CNP or placebo (T30), and after angiotensin II (T60). Results: Infusion of CNP had no significant effects on systemic or pulmonary haemodynamics or on baseline reninangiotensin system activity compared with placebo. Infusion of angiotensin II produced significant systemic and pulmonary pressor effects and also stimulated aldosterone secretion. There were, however, no significant differences between the changes induced by angiotensin II (expressed as the difference between T30 and T60) when CNP was infused compared with placebo: change in mean systemic arterial pressure with CNP 26.6(SEM 2.3) mm Hg v placebo 30.3(3.6) mm Hg; change in mean pulmonary artery pressure with CNP 11.7(2.5) mm Hg v placebo 10.9(1.0) mm Hg; change in aldosterone concentration with CNP 219(40) pmol·litre-1 v placebo 242(40) pmol·litre-1. Conclusions: At a dose of CNP which has previously been found to have marked haemodynamic effects in dogs, no effect on systemic or pulmonary haemodynamics was observed in man. Furthermore, CNP had no effect on the aldosterone or pressor responses to infused angiotensin II. The present study would suggest that CNP does not have a circulating endocrine role in cardiovascular homeostasis, although a paracrine role within vascular endothelium is perhaps more likely.

    AB - Objective: The aim was to study the effects of high dose systemic human C-type natriuretic peptide (CNP) infusion in man on systemic and pulmonary haemodynamics and the renin-angiotensin system before and after infusion of angiotensin II. Methods: Eight normal male volunteers were studied on two separate occasions when, after the subjects had been rested to reach a baseline haemodynamic state (T0), infusions of either human CNP (10 pmol·kg-1·min-1) or placebo (5% dextrose) were begun. After 30 min (T30) on each study day, a concomitant infusion of angiotensin II (6 ng·kg-1·min-1) was started, and both infusions ran together for a further 30 min (until T60). Measurements of systemic and pulmonary haemodynamic variables and the activity of the renin-angiotensin system were made at baseline (T0), after 30 min of CNP or placebo (T30), and after angiotensin II (T60). Results: Infusion of CNP had no significant effects on systemic or pulmonary haemodynamics or on baseline reninangiotensin system activity compared with placebo. Infusion of angiotensin II produced significant systemic and pulmonary pressor effects and also stimulated aldosterone secretion. There were, however, no significant differences between the changes induced by angiotensin II (expressed as the difference between T30 and T60) when CNP was infused compared with placebo: change in mean systemic arterial pressure with CNP 26.6(SEM 2.3) mm Hg v placebo 30.3(3.6) mm Hg; change in mean pulmonary artery pressure with CNP 11.7(2.5) mm Hg v placebo 10.9(1.0) mm Hg; change in aldosterone concentration with CNP 219(40) pmol·litre-1 v placebo 242(40) pmol·litre-1. Conclusions: At a dose of CNP which has previously been found to have marked haemodynamic effects in dogs, no effect on systemic or pulmonary haemodynamics was observed in man. Furthermore, CNP had no effect on the aldosterone or pressor responses to infused angiotensin II. The present study would suggest that CNP does not have a circulating endocrine role in cardiovascular homeostasis, although a paracrine role within vascular endothelium is perhaps more likely.

    U2 - 10.1016/S0008-6363(96)88554-3

    DO - 10.1016/S0008-6363(96)88554-3

    M3 - Article

    VL - 29

    SP - 108

    EP - 111

    JO - Cardiovascular Research

    JF - Cardiovascular Research

    SN - 0008-6363

    IS - 1

    ER -